系统综述:丙型肝炎病毒相关Child C级肝硬化患者的无干扰素方案
该系统综述通过Medline检索及会议摘要筛选,纳入7篇全文和2篇会议摘要,并参考一项意大利真实世界试验数据,评估无干扰素直接抗病毒药物方案在Child C级肝硬化丙型肝炎患者中的疗效。共240例Child C患者中228例有治疗结局数据,加权平均SVR12为74.9%(95%CI:65.6-82.4%),治疗疗程(24周或12周)及是否加用利巴韦林均不影响该 rates。索磷布韦/司美匹韦方案SVR12为65.4%,索磷布韦/达拉他韦为76.0%,索磷布韦/来迪派韦为83.0%。
要点
- Child C级肝硬化丙型肝炎患者接受无干扰素方案治疗的加权平均SVR12为74.9%(95%CI:65.6-82.4%)。
- 索磷布韦/来迪派韦方案SVR12为83.0%,索磷布韦/达拉他韦为76.0%,索磷布韦/司美匹韦为65.4%。
- 治疗疗程(24周或12周)及加用利巴韦林均不影响SVR12 rates。
核心结论
- MELD评分的改善强烈提示丙型肝炎病毒阳性Child C级肝硬化患者应接受这些药物治疗。
研究设计与样本
- 系统综述:通过Medline检索识别直接抗病毒药物治疗Child C患者的研究,交叉参考已识别研究的引文,并核查欧洲肝脏研究学会(EASL)和美国肝病研究学会(AASLD)会议摘要。
- 从649条记录中保留7篇全文和2篇会议摘要进行分析,并参考一项意大利真实世界试验的数据。
- 10项试验共评估240例Child C患者,其中228例有治疗结局信息。
主要发现
- 总体加权平均持续病毒学应答(SVR12)为74.9%(95%CI:65.6-82.4%)。
- 治疗疗程(24周或12周)及加用利巴韦林均不影响SVR12 rates。
- 索磷布韦/司美匹韦方案加权SVR12为65.4%(95%CI:46.8-80.2),索磷布韦/达拉他韦为76.0%(95%CI:54.4-89.3%),索磷布韦/来迪派韦为83.0%(95%CI:73.4-89.6%)。
- 在提供相关数据的研究中,12.1%的患者记录到治疗后复发,61.1%的患者MELD评分改善≥2分。
局限性
- 部分研究未提供治疗后复发率或功能改善的信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether the efficacy and long-term outcome of treating patients with hepatitis C virus (HCV)-positive cirrhosis with the new protease inhibitors will extend to those with Child C cirrhosis. AIM: To assess the effectiveness of the interferon-free regimens in Child C cirrhotic patients with HCV infection. METHODS: A systematic Medline search was conducted to retrieve studies describing the treatment of Child C patients with direct-acting agents. Citations from identified studies were cross-referenced and abstracts from European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD) meetings were checked. Extracted data were evaluated using a meta-analysis to calculate a weighted response rate. RESULTS: Seven full-text records and two conference abstracts were retained for analysis from the 649 records identified. Data from an Italian real-life trial were also interrogated. Information on treatment outcome was available for 228 of the 240 Child C patients evaluated in the 10 trials. Overall, the weighted mean sustained virological response (SVR12) was 74.9% (95% CI: 65.6-82.4%). Neither duration of treatment (24 or 12 weeks), nor addition of ribavirin influenced these rates. The weighted SVR12 was 65.4% (95% CI: 46.8-80.2) after sofosbuvir/simeprevir, 76.0% (95% CI: 54.4-89.3%) after sofosbuvir/daclatasvir and 83.0% (95% CI: 73.4-89.6) after sofosbuvir/ledipasvir. Some studies did not provide information on the rate of post-treatment relapse or functional improvement. However, in those studies that did provide such data, a relapse was documented in 12.1% of patients and an improvement of ≥2 points on the model for end-stage liver disease (MELD) score in 61.1% of patients. CONCLUSION: The improvement in MELD scores strongly suggests HCV-positive patients with Child C cirrhosis should be treated with these agents.
引用
- Guarino M, Morisco F, Valvano MR, et al. Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis. Aliment Pharmacol Ther. 2017. PMID: 28261822. doi:10.1111/apt.14017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。